What percentage of the general adult population has nasal (sinus) polyps?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Prevalence of Nasal Polyps in the General Population

Nasal polyps affect approximately 2-4% of the general adult population 1. This prevalence estimate is consistently reported across multiple high-quality guidelines and is supported by population-based research studies.

Key Epidemiological Details

Overall Population Prevalence

  • General population: 2-4% is the most widely cited range from authoritative guidelines 1
  • Recent population-based studies confirm this range:
    • Swedish population study: 2.7% (95% CI: 1.9-3.5) 2
    • Austrian population study: 1.95% (adjusted for age and gender) 3
    • Polish population study: 0.52% (though this may reflect underreporting in registry data) 4

Age-Related Patterns

  • Nasal polyps typically occur after age 40 years 1
  • Prevalence increases significantly with age:
    • Peaks at 5% in adults ≥60 years 2
    • Highest rates in the 75-79 age group (up to 10% in some populations) 4

Gender Distribution

  • No significant sex preference according to recent large population studies 1
  • Earlier studies suggested a 2:1 male-to-female ratio, but this has not been confirmed in more recent, higher-quality population-based research 1, 2

Special Population Considerations

High-Risk Groups with Elevated Prevalence

  • Adults with asthma: 7-15% 1
  • Children with cystic fibrosis: up to 50% 1
  • Patients with aspirin-exacerbated respiratory disease (AERD): 13-40% of those with nasal polyposis have this condition 1

Comorbid Conditions

  • 10-15% of patients with allergic rhinitis also have nasal polyps 1
  • However, allergy does not appear to be a causative factor for polyp formation 1

Clinical Context

The 2-4% prevalence translates to a substantial disease burden given that:

  • Chronic nasal polyposis is associated with reduced quality of life and increased risk of sleep disturbances 1
  • Common presenting symptoms include rhinorrhea (39%), nasal congestion (31%), and anosmia (29%) 1
  • The condition requires ongoing medical management or surgical intervention in many cases

Important Caveats

  • Prevalence estimates may vary by geographic region and detection methods used
  • Studies using nasal endoscopy (the gold standard) detect more polyps than those relying on anterior rhinoscopy alone 5
  • Registry-based studies may underestimate true prevalence due to underdiagnosis in asymptomatic or mildly symptomatic individuals 4

References

Guideline

the diagnosis and management of rhinitis: an updated practice parameter.

Journal of Allergy and Clinical Immunology, 2008

Research

Prevalence of nasal polyps in adults: the Skövde population-based study.

The Annals of otology, rhinology, and laryngology, 2003

Research

Prevalence and Symptom Burden of Nasal Polyps in a Large Austrian Population.

The journal of allergy and clinical immunology. In practice, 2021

Research

Recorded prevalence of nasal polyps increases with age.

Postepy dermatologii i alergologii, 2021

Guideline

clinical practice guideline: adult sinusitis update.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2025

Related Questions

In a patient with chronic rhinosinusitis who has persistent symptoms despite maximal medical therapy and evidence of type‑2 inflammation, what are the indications for initiating biologic therapy, which biologics are recommended, their dosing regimens, and how should response be monitored?
I am experiencing nasal fullness and occasional nosebleeds; could this be caused by a nasal polyp?
In a 69-year-old patient with MRI findings of chronic diffuse cerebral atrophy, focal volume loss in the right precentral gyrus and left superior frontal gyrus, gliosis and hemosiderosis consistent with prior trauma, and sinonasal polyposis, what is the interpretation and recommended management?
Which intranasal corticosteroid spray is most effective for treating nasal polyps with a burning sensation?
Which specialist should a patient with nasal polyps be referred to?
What red‑flag signs indicate a serious underlying cause in a child with back pain?
How should I assess and manage a patient’s atherosclerotic cardiovascular disease (ASCVD) risk, including appropriate statin intensity, lifestyle modifications, and additional lipid‑lowering therapies?
What is the recommended pharmacologic management of fibromyalgia based on the predominant symptom (pain, sleep disturbance/fatigue, mood, or cognitive dysfunction)?
Is serum creatinine included in a comprehensive metabolic panel (CMP), and is creatinine clearance reported directly in the CMP?
Should a patient recovering from a fracture who has severe osteoporosis or is at high risk for another fracture receive anti‑osteoporotic therapy?
Is a right‑heart catheterization recommended to further evaluate an estimated right ventricular systolic pressure of 80–90 mmHg noted on echocardiography?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.